Vimarsana
Biggest News Aggregation in the World

Xiaodong Yang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Xiaodong Yang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Xiaodong Yang Today - Breaking & Trending Today

Twenty-five S&T faculty members receive tenure, promotions - Vimarsana News

Twenty-five S&T faculty members receive tenure, promotions

Twenty-five faculty members at Missouri University of Science and Technology will receive promotion and/or tenure, effective Sept. 1. Those faculty members are:

Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting - Vimarsana News

Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma -... | June 3, 2023

Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its - Vimarsana News

Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its

- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in...

Pyxis Oncology : to Acquire Apexigen - Form 8-K - Vimarsana News

Pyxis Oncology : to Acquire Apexigen - Form 8-K

Pyxis Oncology to Acquire Apexigen Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate development Commercially and clinically validated APXiMAB... | May 24, 2023

Apexigen Announces Review of Strategic Alternatives and Restructuring - Vimarsana News

Apexigen Announces Review of Strategic Alternatives and Restructuring

27.02.2023 - SAN CARLOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) - Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced ... Seite 1